Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis

Table 2 Meta-analysis of VDR Cdx2 polymorphism and prostate cancer risk

		Homozygote (AA vs. GG)			Heterozygote (GA vs. GG)			Dominant model (AA + GA vs. GG)			Recessive model (AA vs. GA + GG)
Analysis	N	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)	OR (95 % CI)	P	I² (%)
Overall	9	1.11 (0.93–1.33)	0.23	32.3	0.97 (0.88–1.06)	0.53	12.9	0.99 (0.91–1.08)	0.80	28.4	1.12 (0.95–1.31)	0.16	17.6
Ethnicity
Caucasian	6	1.13 (0.92–1.39)	0.23	23.0	0.93 (0.84–1.03)	0.201	0	0.96 (0.88–1.06)	0.45	4.4	1.15 (0.94–1.41)	0.15	16.7
African American	1	1.80 (0.97–3.32)	0.06	—	1.54 (0.81–2.92)	0.18	—	1.70 (0.94–3.10)	0.08	—	1.26 (0.91–1.75)	0.16	—
Hispanic White	1	0.49 (0.17–1.36)	0.17	—	0.83 (0.52–1.31)	0.43	—	0.77 (0.50–1.19)	0.24	—	0.52 (0.18–1.43)	0.20	—
Mixed	1	0.94 (0.58–1.50)	0.80	—	1.15 (0.91–1.44)	0.22	—	1.12 (0.90–1.39)	0.31	—	0.89 (0.56–1.42)	0.64	—
Source of control
PB	8	1.11 (0.92–1.33)	0.259	40.7	0.95 (0.86–1.04)	0.32	0	0.97 (0.89–1.06)	0.54	23.8	1.12 (0.95–1.32)	0.16	27.7
HB	1	1.11 (0.93–1.32)	0.686	—	1.26 (0.88–1.80)	0.19	—	1.25 (0.89–1.75)	0.19	—	1.07 (0.52–2.18)	0.85	—
HWE in controls
Yes	8	1.15 (0.95–1.40)	0.133	34.3 %	0.97 (0.89–1.07)	0.65	22.1	0.99 (0.91–1.09)	0.99	34.6	1.15 (0.97–1.36)	0.09	20.2
No	1	0.87 (0.54–1.40)	0.58	—	0.91 (0.69–1.21)	0.53	—	0.90 (0.69–1.17)	0.46	—	0.90 (0.57–1.43)	0.67	—

P P values for Z test, OR odds ratio, CI confidence intervals, HB hospital–based studies, PB population-based studies, HWE Hardy–Weinberg equilibrium

ISSN: 1471-2407